Executive summary: US Patent 9,283,280 claims an intranasal composition that combines a 5‑HT receptor agonist (specified triptans, including sumatriptan) with an alkylsaccharide surfactant defined by C10 to C16 alkyl chain length, where the formulation must drive fast systemic exposure (eg Tmax <20 min, Cmax >15 ng/mL) and can further require AUC0–1 hr and Cmax fold-enhancement versus a comparator formulation lacking the alkylsaccharide. The claim set is heavily performance-defined (exposure metrics, dose/Cmax ratios, early AUC, early plasma levels), and the most enforceable “core” appears to be the specific alkylsaccharide class (β‑D‑maltoside C10–C16) plus intranasal + fast pharmacokinetics. Design-around pressure is likely highest for any generic or branded entrant attempting to match systemic exposure while using different penetration enhancers, different surfactant identity, or different delivery geometry/dose that fails the exposure thresholds.
What does US Patent 9,283,280 claim and what is the key inventive scope?
Answer (core claim architecture): The patent’s independent claim (claim 1) requires all of the following in one composition:
- Therapeutically effective amount of a 5‑HT receptor agonist selected from: sumatriptan, naratriptan, rizatriptan, eletriptan, frovatriptan, almotriptan, zolmitriptan, salts, or combinations.
- An alkylsaccharide with an alkyl chain of 10–16 carbons (C10–C16).
- Formulated for intranasal administration.
- Performance constraints:
- Tmax < ~20 minutes
- Cmax > 15 ng/mL
- Dependent claims narrow with quantitative surfactant concentration, specific alkylsaccharide identities, additional route coverage, and multiple pharmacokinetic boost requirements (fold increases in AUC0–1 hr and Cmax; early timepoint concentration targets; dose/Cmax ratios).
1) How broad is the drug component scope?
Claim 1 specifies a closed list of triptans. That means the patentee’s scope is strong against entrants using the named actives (or salts/combos), but the claim does not extend to other 5‑HT agonists outside that list. Dependent claims add several sumatriptan-specific exposure targets (claims 17–20).
Practical implication: A competitive product using sumatriptan or another listed triptan is inside the drug-entity scope if it also meets the alkylsaccharide + intranasal + PK thresholds.
2) How broad is the alkylsaccharide scope?
Claim 1 uses a functional definition: alkylsaccharide having an alkyl chain with 10 to 16 carbons. Dependent claim 3 narrows to explicit candidates: undecyl‑β‑D‑maltoside through tetradecyl‑β‑D‑maltoside (plus combinations).
Practical implication for infringement risk:
- A formulation using a different saccharide backbone (not β‑D‑maltoside) but still meeting C10–C16 can still land in claim 1 if it is an “alkylsaccharide” as construed.
- A formulation using C8/C9 or C17+ alkyl chain length is more likely to avoid claim 1’s alkyl-length element.
- A formulation using non-alkylsaccharide penetration enhancers (eg bile salts, cyclodextrins, fatty acids, surfactant systems) is more likely to avoid the claim element unless those excipients still qualify as “alkylsaccharides” under claim construction.
3) How strict are the PK thresholds?
The independent claim requires both:
- Tmax < ~20 min
- Cmax > 15 ng/mL
Dependent claims then add more demanding, time-bounded and ratio-based constraints:
- AUC0–1 hr enhancements (eg ≥1.3× or ≥1.5×)
- Cmax enhancements (eg ≥1.3×)
- Concentration comparisons between early (10–15 min) and late (60 min) timepoints (eg ≥1.3× or ≥1.5×)
- Maximum concentration timepoint constraints (eg Cmax at <20 min)
- AUC0–1 hr > 10 ng·hr/mL
- dose/Cmax ratio thresholds (eg >1×10^6 mL−1; >1.15×10^6 mL−1)
Practical implication: In practice, these are the elements most likely to break infringement arguments because they are assay- and protocol-dependent. Any challenge that the competitor does not achieve the same PK performance under the claim’s comparator definition can narrow risk quickly.
Which claim elements are likely “core” versus “peripheral”?
Likely core elements (claim 1 essentials)
- Intranasal formulation
- Triptan selection (sumatriptan etc.)
- Alkylsaccharide presence with C10–C16 alkyl chain
- PK thresholds: Tmax <20 min and Cmax >15 ng/mL
Likely peripheral elements (dependent tightening)
- Alkylsaccharide concentration range: 0.05% to 2% (claim 2)
- Specific identity: undecyl‑, dodecyl‑, tridecyl‑, tetradecyl‑β‑D‑maltoside (claim 3)
- Route expansion (claim 4): includes additional delivery routes beyond intranasal, though claim 4 is dependent and must still incorporate claim 1’s independent features
- Quantified AUC0–1 hr and Cmax fold-enhancement (claims 5–6)
- Timepoint concentration metrics (claims 7–10)
- Absolute exposure thresholds (claims 11 and 16)
- Dose/Cmax ratio thresholds (claims 12–13)
- Tmax tightened to <15 min (claim 14)
- Sumatriptan-specific early plasma concentration levels (claims 17–20)
Enforcement posture: For many disputes, the patentee will anchor on claim 1 and fall back to one or more dependent claims that match the competitor’s dosing and PK results.
How do the dependent claims map to formulation and PK “must-haves”?
Surfactant concentration and identity
| Claim |
Requirement |
What it narrows |
| 2 |
Alkylsaccharide concentration 0.05% to 2% |
formulation composition window |
| 3 |
Alkylsaccharide is undecyl/dodecyl/tridecyl/tetradecyl‑β‑D‑maltoside |
specific excipient set |
Route language
| Claim |
Requirement |
| 4 |
Administration into circulatory system via oral, ocular, intranasal, nasolacrimal, inhalation, pulmonary, sublingual, buccal, or CSF |
Because claim 4 is dependent on claim 1, any infringing product must still satisfy claim 1’s intranasal formulation requirement unless claim construction treats “intranasal” in claim 1 broadly for the claim 4 dependent limitation. The safest read for infringement is that claim 4 adds other routes only if claim 1’s intranasal formulation is satisfied in the broader “formulated for intranasal administration” sense.
Early exposure enhancement
| Claim |
Early exposure metric |
| 5 |
AUC0–1 hr fold: about 1.3× or 1.5× or greater vs absence of alkylsaccharide |
| 6 |
Cmax fold: about 1.3× or greater vs absence of alkylsaccharide |
| 9 |
Cmax achieved within <20 min when alkylsaccharide concentration is 0.05–0.2% |
| 10 |
Sustained level at 60 min: concentration at 60 min ≥0.25× Cmax |
Timing and magnitude thresholds
| Claim |
Specific constraint |
| 7 |
Plasma/blood level at 10–15 min is ≥1.3× or 1.5× relative to 60 min |
| 8 |
Cmax occurs <20 min and is ≥1.3× or 1.5× vs antagonist at 60 min |
| 11 |
Cmax ≥17 ng/mL |
| 14 |
Tmax <15 min |
| 16 |
AUC0–1 hr >10 ng·hr/mL |
Dose-normalized exposure
| Claim |
Requirement |
| 12 |
dose/Cmax >1×10^6 mL−1 |
| 13 |
dose/Cmax ≥1.15×10^6 mL−1 |
These ratio claims can be powerful in litigation because they connect dose and exposure in a single element, reducing arguments that “lower dose” alone explains exposure differences.
Sumatriptan-specific early plasma levels
| Claim |
Sumatriptan exposure target |
| 17 |
≥5 ng/mL in 5 min or less |
| 18 |
about 20 mg sumatriptan and ≥16 ng/mL in 20 min or less |
| 19 |
≥5 ng/mL in 2 min or less |
| 20 |
≥10 ng/mL in 15 min or less |
If an accused product’s clinical PK study does not include timepoints that correspond to these exact thresholds, the patentee’s path often becomes: (i) expert reconstruction, (ii) reliance on sampling schedules from labels or bridging studies, and (iii) resort to additional test data. Those are litigation posture variables, but the claim set is clearly drafted to reward early-onset intranasal PK.
What patents or claim elements create the most enforceable exclusion around intranasal triptans?
Most enforceable “exclusion zones”
- Alkylsaccharide C10–C16 used as a penetration/absorption enhancer with intranasal delivery.
- Fast systemic PK outcome measured as Tmax <20 min and Cmax >15 ng/mL.
- For sumatriptan, the presence of early plasma thresholds (2–20 minutes).
Weakest leverage for enforcement
- Any product that does not hit both Tmax and Cmax thresholds simultaneously.
- Any product that uses alkyl chain lengths outside C10–C16 or avoids “alkylsaccharide” definitions.
- Any product that uses triptans not on the listed closed list (outside sumatriptan/naratriptan/rizatriptan/eletriptan/frovatriptan/almotriptan/zolmitriptan and salts).
How does a generic or branded intranasal triptan design around US 9,283,280?
Design-around pathways likely used
- Change excipient class: avoid alkylsaccharide with C10–C16 alkyl chain.
- Change chain length: use C9/C8 or C17+ analogs if formulation science allows.
- Change surfactant identity within the “alkylsaccharide” term: if the claim construction limits “alkylsaccharide” to specific sugar backbones (eg β‑D‑maltoside), using a different carbohydrate headgroup can reduce claim 3 coverage while still potentially touching claim 1 depending on breadth.
- Fail the PK performance thresholds: design to hit acceptable Tmax/Cmax for safety but not meet Tmax <20 min and Cmax >15 ng/mL, or not meet sumatriptan’s early ng/mL targets.
Where litigation risk concentrates
If a competitor’s product targets the same clinical goal (rapid onset intranasal triptan) and uses alkylsaccharide excipients in the C10–C16 range, the probability of meeting the claim’s performance constraints increases. In that scenario, the remaining carveouts are:
- excipient identity and concentration (claim 2–3),
- early AUC/Cmax fold comparisons (claims 5–6),
- dose/Cmax ratio thresholds (claims 12–13),
- and sumatriptan timepoint thresholds (claims 17–20).
What would infringement analysis focus on in US litigation around this patent?
Claim-by-claim infringement checklist
For a suspected accused product, plaintiff-side infringement analysis typically maps like this:
- Is the active ingredient one of the listed triptans (or salt/combination)?
- Is the formulation intranasal and does it include an alkylsaccharide with C10–C16 chain?
- Do PK data show Tmax <~20 min and Cmax >15 ng/mL?
- If yes, identify which dependents are additionally met:
- Alkylsaccharide concentration in 0.05–2% (claim 2)
- β‑D‑maltoside identity (claim 3)
- early AUC0–1 hr and fold-enhancements (claims 5 and 6)
- sumatriptan timepoint levels (claims 17–20)
Comparator issues (fold-enhancement claims)
Claims 5–6 reference “in the absence of the alkylsaccharide.” Litigation typically treats this as a need for a comparator formulation. If the accused product never tested against a “no alkylsaccharide” comparator under matched conditions, the patentee often relies on experimental rebuilding or prior reference formulations. Defense strategies usually argue that any comparator differs in ways that invalidate the “absence” comparison.
What is the likely patent landscape position of US 9,283,280 versus earlier and later intranasal delivery patents?
Because the text provided is limited to the claim set and does not include the patent title, assignee, priority dates, specification-dependent definitions, prosecution history, or any related patents, a complete landscape tying priority/expiration, continuations, or family breadth cannot be established from this record.
What can be extracted from the claims alone is the patent’s technical theme:
- Tripan + alkylsaccharide (C10–C16) + intranasal + fast PK outcomes.
This theme typically overlaps with other intranasal drug delivery IP categories:
- nasal absorption enhancers and penetration aids,
- formulation buffers and solubilizers that affect absorption kinetics,
- and nasal dose-form technology intended to reach rapid Tmax and higher Cmax.
How do the claims affect licensing, settlement, and launch timing decisions?
Licensing leverage
The combination of:
- a closed triptan list,
- a chemically specific penetration enhancer class (alkylsaccharides with defined alkyl length),
- and hard PK targets
creates a licensing posture where the biggest economic value is concentrated in:
- products using sumatriptan or other listed triptans intranasally,
- that incorporate the alkylsaccharide excipient class,
- and that demonstrate the same fast exposure profiles.
Settlement triggers
Settlements usually pivot on whether an accused formulation can be shown, with credible PK data, to miss at least one mandatory element in claim 1:
- Tmax threshold,
- Cmax threshold,
- or alkylsaccharide definition.
If it misses claim 1, dependent claims are generally moot. If it hits claim 1, defenses shift to dependents (concentration, identity, fold comparisons, ratio, and sumatriptan timepoints).
Key Takeaways
- US 9,283,280 is built around intranasal triptans (specified list) formulated with an alkylsaccharide (C10–C16) to achieve fast systemic pharmacokinetics.
- The most litigation-relevant elements are Tmax <~20 minutes and Cmax >15 ng/mL, plus sumatriptan-specific early plasma targets.
- Dependent claims narrow the enhancer to 0.05%–2% and specific β‑D‑maltosides, and they add stringent performance metrics including fold-enhanced early AUC0–1 hr, dose/Cmax ratios, and sustained levels at 60 minutes.
- Generic or competitor design-arounds most plausibly succeed by avoiding the alkylsaccharide class/chain length or by failing the PK performance thresholds rather than by small formulation tweaks.
FAQs
-
How can a competitor argue non-infringement if they match Cmax but miss Tmax?
Focus on claim 1’s dual requirement that Tmax is under ~20 minutes while Cmax exceeds 15 ng/mL; missing either breaks claim 1.
-
Do sumatriptan-specific claims 17–20 require the same dose as the independent claim?
Claim 18 explicitly ties to about 20 mg; claims 17, 19, 20 specify concentration-time thresholds without the same fixed dose language.
-
What matters most for fold-enhancement claims 5 and 6 in litigation?
The “absence of alkylsaccharide” comparator under matched conditions, because those dependents require demonstrable fold differences versus that baseline.
-
Can a product use a different alkylsaccharide headgroup and still infringe claim 1?
Potentially yes, because claim 1 is defined by alkyl chain length (C10–C16) and “alkylsaccharide” as a category; headgroup-only differences are only safe if they fall outside the claim construction of “alkylsaccharide.”
-
If an accused product uses an intranasal route, does claim 4 expand route coverage for infringement?
Claim 4 is dependent, so infringement still requires the underlying claim 1 limitations; claim 4 signals additional route contexts but does not erase claim 1 intranasal requirements.
References (APA)
- United States Patent No. 9,283,280. Claims provided in prompt.
